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A best evidence topic in surgery was written according to a structured protocol. The question addressed
was “In cancer patients undergoing oesophageal or gastric resection for cancer and requiring
postoperative nutritional support, does enteral immunonutrition confer additional clinical beneﬁts as
compared to standard enteral nutrition? Two hundred and ﬁfty-eight papers were identiﬁed by a search
of the MEDLINE and EMBASE databases, of which six randomized controlled trials represented the best
evidence to answer this clinical question. The authors, journal, date and country of publication, patient
group, study group, relevant outcomes and results of these papers were tabulated. All six of these
randomised controlled trials compared the clinical beneﬁts of standard enteral nutrition with those of
enteral nutrition supplemented with a variety of immune-modulating substances. The studies failed to
demonstrate consistent differences in patients’ postoperative clinical course, complications, length of
hospital stay and inﬂammatory marker levels. Hence although there is reasonable evidence to suggest
that immunonutrition improves humoral immunity as opposed to cellular immunity, this improvement
does not result in reductions in infection rates or reduced hospital stay. There is currently not enough
evidence to recommend routine immunonutrition in all patients undergoing oesophageal or gastric
resection for cancer.
 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
A best evidence topic was constructed according to a structured
protocol as described in a previous publication.12. Clinical scenario
You are in an upper gastrointestinal malignancy multi-
disciplinary clinic discussing a patient scheduled to undergo
resection for a gastro-oesophageal junctional tumour. It has been
decided that following surgery he will receive enteral nutritional
support. The dietician suggests that instead of standard enteral
feed, he should be given enteral immunonutrition (EIN). You
resolve to check the literature to determine whether or not
postoperative enteral immunonutrition (EIN) confers any addi-
tional clinical beneﬁt as compared to standard enteral nutrition
(SEN)..
ciates Ltd. Published by Elsevier Lt3. Three-part question
In patients undergoing oesophagogastric resection for cancer
does postoperative enteral immunonutrition as compared to
standard enteral nutrition confer additional clinical beneﬁts?
4. Search strategy
The following string was run using the PubMed and EMBASE
interfaces:
[((gastr* OR stomach OR resection).ti,ab OR (esophag* OR
oesophag*).ti,ab) AND (immunonutr*.ti,ab OR (immune AND
nutr*)) AND enteral.ti,ab].
The search was limited to English and duplicate ﬁltered. In
addition, the reference lists of relevant papers were searched. The
search was current as of April 2012.
5. Search outcome
Two hundred and ﬁfty-eight papers were found using the re-
ported search, of which 228 were irrelevant to the clinical question.
Of the 30 remaining potentially relevant papers, 5 were literature
reviews and 17 papers analysed patients with malignancies otherd. All rights reserved.
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studies compared EIN with SEN in patients with oesophagogastric
cancers. Two of these were retrospective case analyses and the
remaining six were randomized controlled trials. These six
randomized controlled trials (RCTs) were identiﬁed as representing
the best evidence to answer this clinical question.
6. Results
The results of the RCTs are summarised in Table 1.
7. Discussion
Oesophagogastric cancers have long been known to be associ-
ated with impairment of nutritional status. As a consequence of
this, it has been suggested that some of these patients may beneﬁt
from enteral feeding immediately following resectional surgery.2 In
addition, the impaired immune response associated with cancer
has led some to suggest that, these patients may beneﬁt from the
addition of immunomodulating compounds in their enteral feeds.
The immune-modulating substances most commonly added to
enteral feeds to form enteral immunonutrition (EIN) are arginine,
ribose nucleic acid (RNA) and omega-3-fatty acids (O-3FA). Argi-
nine, a precursor to nitric oxide synthesis, is a conditionally
essential amino acid that becomes essential during growth and
recovery after injury.2 RNA nucleotide-deﬁcient diets have resulted
in the decreased production of interleukin (IL)-2 and diminished T-
cell responses, suggesting that nucleotides may play role in the
immune response.2 Similarly high level of high O-3FA has been
shown to associated with immunological beneﬁts.2 Although the
addition of these compounds may have theoretical beneﬁts, the
actual clinical efﬁcacy of EIN versus standard enteral nutrition
(SEN) for patients undergoing oesophagogastric resection for
cancer has only been formally assessed in six randomised
controlled trials.
Sakurai et al.3 randomised 30 patients undergoing oesopha-
gectomy to receive either SEN (n ¼ 14) or EIN (n ¼ 16). The patients
EIN group received perioperative Impact regime (Ajinomoto
Pharma Tokyo, Japan), which contains arginine, RNA, and -3 poly-
unsaturated fatty acids, whereas the SEN patients received peri-
operative regular polymeric enteral formula. No difference was
seen in the length of time patients suffered from systemic inﬂam-
matory response syndrome (SIRS), the time they took to resume
oral intake and the length of hospital stay. In terms of biochemical
outcomes, there were no signiﬁcant difference in the levels of C-
reactive protein (CRP) and interleukin (IL)-6. Postoperatively,
serum ornithine and eicosapentoic acid (EPA) levels were the only
amino- and fatty acids, respectively, higher in the EIN group.
However, as these marginal differences were only from 3 to 7 days
after surgery, the authors questioned their signiﬁcance. However,
this trial suggested that perioperative EIN was beneﬁcial in main-
taining humoral immunity rather than cellular immunity because
the EIN group had a signiﬁcantly higher B-cell fraction on post-
operative days (PODs) 5, 7 and 14, serum IgG on POD 3, CD4/CD8
ratio on POD 7 but a lower T-cell fraction. This trial was under-
powered to enable ﬁrm conclusions to be drawn on the effect of EIN
on postoperative clinical outcomes. Although all complications
were proportionally lower in the EIN group, the differences were
not statistically signiﬁcant. This study was limited by low power,
non-disclosure of the randomisation method, the absence of any
blinding and no CONSORT diagram.
Ryan et al.4 randomised 53 patients undergoing oesophagectomy
to receive either SEN (n¼ 25)or EIN (n¼ 28). The EINgroup received5
days of preoperative supplementationof anEPAenriched (2.2 gEPA/d)
enteral feed whilst the SEN group receive an isocaloriﬁc andisonitrogenous standard nutritional feed without EPA. There was no
signiﬁcance difference in the rates of any complications between the
groups. The SEN group lost a mean of 1.8 kg weight and 1.9 kg lean
mass which was signiﬁcantly more than the EIN group who did not
lose any weight or lean mass. Analysis of inﬂammatory and immu-
nological marker proﬁles revealed no signiﬁcant difference in the
levels of CRP, serum amyloid A, prothrombin time, D-dimer, platelets,
IL-6 and -10 and TNF-a between the groups, however the EIN group
had signiﬁcantly lower IL-8 levels. Although this was an RCT, it should
be noted that groups were heterogeneous with respect to gender
distribution and disease with the EIN have signiﬁcantly more
advanced disease. The study was underpowered for an analysis of
postoperative complications and did not examine the full spectrum of
cytokine changes related tonutritional immunomodulation, therefore
no ﬁrm conclusions can be drawn from the cytokine data. However,
the study provides proof of concept that EIN is associated with pres-
ervationof leanbodymasspost-oesophagectomycomparedwithSEN.
Sultan et al.5 randomised 195 patients undergoing surgery for
gastric or oesophageal cancer to three groups: SEN (n ¼ 63) and
omega-3-fatty acid supplemented enteral nutrition (EIN) (n ¼ 66)
and a control group (n¼ 66). The SEN and EIN groups both received
their feeding regimens 7 days before surgery and also for 7 days
after surgery. The control group only received supplementation
with Osmolite (Abbott Nutrition) postoperatively. The SEN group
received Oxepa containing 0.73 g of O-3FAs per 100 mL, 1.5 kcal/
mL with 6.25 g per 100 mL protein and no free arginine or gluta-
mine. The SEN group received Ensure Plus containing 1.5 kcal/mL
with 6.25 g per 100 mL protein. There was no signiﬁcant difference
in the rates of any complications or the length of critical care stay,
hospital stay, morbidity and mortality rates. Unlike Ryan et al.4 no
difference was seen in body weight between groups. However, like
Ryan et al.4 and Sakurai et al.,3 there was no signiﬁcant difference in
the levels of CRP. There was also no signiﬁcant difference between
the groups in monocyte and lymphocyte HLA-DR expression.
Although there was homogeneity between the study groups, only
47% of the patients reached the maximum planned feeding rate
owing to problems with tolerance and/or complications. Overall
this study demonstrated that EIN conferred no advantage in overall
clinical or immunological outcome compared with SEN.
Farreras et al.6 randomised 66 patients undergoing gastrectomy
postoperatively to receive either SEN (n ¼ 30) or EIN (n ¼ 30)
immediately after surgery. The EIN group received Impact
(Novartis Consumer Health, Spain) which contained (per 100 mL)
1.2 g of arginine, 0.12 g of RNA and 3.5 units of O-3FA. The SEN
group received Isosource Proteins (Novartis Consumer Health,
Spain) which contained (per 100 mL) 1.7 units of O-3FA and no
arginine and RNA. Three patients in both arms discontinued the
interventions. The EIN group stayed in hospital for a mean of 13
days, two less than the SEN group (p < 0.05). The SEN group had
a signiﬁcantly higher rate of wound healing complications, suture
failure, infectious and global complications and a lower hydrox-
yproline level (p < 0.05). However, there was no signiﬁcance
difference in the rates of abdominal abscess, dehiscence, sepsis, UTI,
surgical wound and lung infection and mortality. The EIN group
showed both a lower decrease and a faster recovery of lymphocyte
count, total proteins, albumin and pre-albumin levels. Although
this study suggested that EIN may improve surgical wound healing,
it had several limitations. The analysis was not on an intention-to-
treat basis. The groups were heterogeneous i.e. the EIN group was
younger, weighed more and had a higher basal metabolic rate. The
study group also had signiﬁcantly higher basal caloric requirements
than the control group. In addition, it should be noted that the
study was funded by supplier of the immunonutrition formula.
Chen et al.7 randomised 40 patients undergoing gastrectomy
into EIN (n ¼ 20) and SEN (n ¼ 20) groups postoperatively. The EIN
Table 1
Best evidence papers.
Author, date
and country
Study type and level
of evidence
Patient group (EIN ¼ enteral
immunonutrition; SEN ¼ standard
enteral nutrition)
Outcomes Key results Comments
Sakurai et al.,3
2007, Japan
Prospective,
randomized trial,
Level 2
30 patients undergoing oesophagectomy
to receive either SEN (n ¼ 14) or EIN
(n ¼ 16). The patients EIN group
received perioperative Impact
(Ajinomoto Pharmaceutical Company,
Tokyo, Japan) whereas the SEN patients
received perioperative regular polymeric
enteral formula (Ensure, Abbott Japan
Company Ltd., Tokyo, Japan)
Postoperative
complications
(EIN vs. SEN)
Pulmonary complication: 2 (12.5%)
vs. 3 (21.4%)
Pneumonia: 2 (12.5%) 3 (21.4%)
Gastrointestinal complications:
3 (19.6%) vs. 4 (28.5%)
Anastomotic dehiscence: 2 (13.3%)
vs. 3 (21.4%)
Intestinal obstruction: 1 (6.3%)
vs. 1 (6.3%)
Surgical site infection: 1 (6.3%)
vs. 3 (21.4%)
Although all complications were lower
in the EIN arm, none of these
differences were statistically signiﬁcant.
This trial was underpowered to enable ﬁrm
conclusions to be drawn on the effect of EIN
on postoperative clinical outcomes. Although
all complications were proportionally lower
in the EIN group, the differences were not
statistically signiﬁcant.This study was limited
by low power, non-disclosure of the
randomisation method, no blinding and no
CONSORT diagram.
Postoperative
clinical course
No difference in length of SIRS, start of
oral intake postoperative and length of
hospital stay (p > 0.05)
Inﬂammatory and
immunological
marker proﬁles
CRP and IL-6: No difference but data
not presented
WBC count: EIN > SEN (p < 0.05 POD7)
% lymphocyte fraction: EIN > SEN
(p < 0.05 POD 1 and 3)
B-cell fraction: EIN > SEN (p < 0.05,
POD 5,7 and 14)
T-cell fraction: EIN < SEN (p < 0.05,
POD 5,7 and 14)
Serum IgG: EIN > SEN (p < 0.05 POD 3)
CD4:CD8: EIN > SEN (p < 0.05 POD 7)
Other outcomes
Serum amino
acid proﬁles
Ornithine: EIN > SEN POD5 (p < 0.05)
Serum fatty acid
proﬁles
EPA: EIN > SEN (p < 0.05 POD7)
n  3/n  6 ratio: EIN > SEN
(p < 0.05, POD7)
Ryan et al.,4
2009
Ireland
Prospective,
double-blinded,
randomised trial
Level II
53 patients undergoing oesophagectomy
were randomised to receive either SEN
(n ¼ 25) or EIN (n ¼ 28). The EIN group
received 5 days of preoperative
supplementation of an EPA enriched
(2.2 g EPA/d) enteral feed (ProSure,
Abbott Laboratories, Ireland) whilst the
SEN group receives an isocaloriﬁc and
isonitrogenous standard nutritional feed
(Ensure Plus, Abbott Laboratories,
Ireland) without EPA.
Postoperative
complications
(EIN vs. SEN)
No signiﬁcance difference in any
complications:
Sepsis: 5 (18%) vs. 2 (8%)
Anastomotic leak: 1 (4%) vs. 1 (4%)
Renal failure: 1 (4%) vs. 3 (12%)
Wound infection: 0 (0%) vs.2 (8%)
Pneumonia: 7 (25%) vs. 5 (20%)
ARDS: 1 (4%) 0 (0%) 1.000
SIRS >3 d: 3 (18%) 7 (41%) 0.259
SIRS >5 d: 1 (6%) 4 (24%) 0.335
This study had several limitations. The EIN
group had signiﬁcantly more males than
females and more positive nodes, making the
groups heterogeneous. Analysis was not done
on an intention-to-treat basis. The study was
underpowered for an analysis of postoperative
complications and of the full spectrum of
cytokine changes relating to nutritional
immunomodulation, therefore no ﬁrm
conclusions can be drawn from the cytokine
data.However, the study provides proof of
concept that EIN is associated with
preservation of lean body mass
post-oesophagectomy compared with SEN.
Postoperative
clinical course
Not reported
Inﬂammatory and
immunological
marker proﬁles
No signiﬁcant difference in CRP, IL-6
and SAA between groups (p > 0.05)
No signiﬁcant difference in PT, D-dimer
and platelets between groups (p > 0.05)
IL-8: EIN < SEN (p < 0.05 POD7, 14)
IL-10 and TNF-a: p > 0.05
Other outcomes
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Plasma and cell
membrane fatty acid
composition
In EIN group, eicosapentoic acid
signiﬁcantly increased in serum
(p < 0.05) but remained constant in
the SEN group (p > 0.05).
Body composition
analysis
The SEN group lost a signiﬁcant amount
of weigh and lean mass whereas
the EIN group remained constant
Sultan et al.,5
2012
UK
Prospective,
double-blinded,
randomised trial
Level II
195 patients undergoing respective
surgery for gastric or oesophageal cancer
were randomised to receive either SEN
(n ¼ 63), omega-3-fatty acid
supplemented enteral nutrition (EIN)
(n ¼ 66) 7 days before and after surgery,
or to postoperative supplementation
alone (control) (n ¼ 66).The SEN group
received Oxepa (Abbott Nutrition,
Maidenhead, UK) which contains 0.73 g
of O-3FAs per 100 mL, 1.5 kcal/mL with
6.25 g per 100 mL protein and no free
arginine or glutamine. The SEN group
received Ensure Plus (Abbott Nutrition),
containing 1.5 kcal/mL with 6.25 g per
100 mL protein. The control group
received enteral Osmolite (Abbott
Nutrition) postoperatively only.
Postoperative
complications
(EIN vs. SEN)
Wound infection: 9 vs. 9
Urinary tract infection: 12 vs. 7
Respiratory tract infection: 20 vs. 23
Intra-abdominal abscess: 0 vs. 0
Feeding tube infection: 2 vs. 1
Infective diarrhoea: 3 vs. 2
Septicaemia: 3 vs. 2
Anastomotic leak: 4 vs. 7
Total no. of infections: 54 vs. 51
No. of patients with an infective
complication: 33 (50) vs. 34 (54)
There was no statistically signiﬁcant
difference in any of the complications.
Although there was homogeneity between
the study groups, only 46.7% of the patients
reached the maximum planned feeding rate
owing to problems with tolerance and/or
complications and anthropometric data may
be limited by inter-rater variability, limiting
the strength of conclusions. In this study, EIN
conferred no advantage in overall clinical or
immunological outcome compared with SEN.
Therefore, this study failed to elucidate the
optimal quantity and combination of nutrients,
the timing of their delivery and the patient
group(s) most likely to beneﬁt from
immunonutrition.Postoperative
clinical course
Critical care stay (days): 2 (0e75)
vs. 4 (0e34)
Hospital stay (days): 18 (4e141)
16 (11e116)
Overall morbidity: 43 (65) vs. 37 (59)
Death: 2 (3) vs. 2 (3)
None of these differences were
statistically signiﬁcant.
Inﬂammatory and
immunological
marker proﬁles
CRP: no signiﬁcant difference although
EIN group had lower levels than the
SEN group on all days of the study
(p > 0.05)
HLA-DR expression: No signiﬁcant
difference between the groups in
monocyte and lymphocyte HLA-DR
expression (p > 0.05)
Other outcomes
Serum fatty acid
proﬁles
Arachidonate: EIN > SEN (p < 0.05)
Eicosapentoate: EIN > SEN (p < 0.05)
DHA: EIN > SEN (p < 0.05)
O-6FA/O-3FA ratio: EIN < SEN (p < 0.05)
Farreras et al.,6
2004
Spain
Prospective,
double-blinded,
randomised trial
Level II
66 patients undergoing gastrectomy
were randomised postoperatively to
receive either SEN (n ¼ 30) or EIN
(n ¼ 30) immediately after surgery. The
EIN group received Impact (Novartis
Consumer Health, Spain) which
contained, for every 100 mL, 1.2 g of
arginine, 0.12 g of RNA and 3.5
(unknown units) of O-3FA. The SEN
group received Isosource Proteins
(Novartis Consumer Health, Spain)
which contained, for every 100 mL, 1.7
(unknown units) of O-3FA and no
arginine and RNA
Postoperative
complications
The SEN group had a signiﬁcantly
higher rate of wound healing
complications, suture failure, infectious
and global complications (p < 0.05).
No signiﬁcance difference in: abdominal
abscess, wound dehiscence, sepsis, UTI,
surgical wound and lung infection, and
mortality.
Although this study suggested that EIN may
improve surgical wound healing, it had
several limitations. The analysis was not on
an intention-to-treat basis. The groups were
heterogeneous: the EIN group was younger,
weighed more and had a higher BMR and
caloriﬁc intake. It was not clear whether all
operations were carried out by one or more
surgeons. Also, the study was funded by
supplier of the immunonutrition formula.
Postoperative
clinical course
Length of hospital stay: EIN mean
13 days vs. SEN mean 15 days (p < 0.05)
Inﬂammatory and
immunological
marker proﬁles
EIN patients show both a lower decrease
and a faster recovery of lymphocyte
count, total proteins, albumin and
pre-albumin levels (p < 0.05).
Hydroxyproline levels: EIN 59.7 nmol
vs.SEN 28 nmol (p < 0.05)
40 patients undergoing gastrectomy
were randomised to receive either EIN
Postoperative
complications
Not reported The limitations of this study include that
the demographics of the groups were not
(continued on next page)
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Table 1 (continued )
Author, date
and country
Study type and level
of evidence
Patient group (EIN ¼ enteral
immunonutrition; SEN ¼ standard
enteral nutrition)
Outcomes Key results Comments
Chen et al.7
2005
China
Prospective,
randomised trial
Level II
(n ¼ 20) and SEN (n ¼ 20) groups
postoperatively. The EIN group
received (Stresson, Nutricia China,
Shanghai, China), a feed enriched with
0.89 g of arginine, 1.3 g of glutamine
and an O-3FA:O-6FA ratio of 3.45:1 for
every 100 mL. The SEN grouped
received Nutrison (Nutricia), a feed
containing with 0.16 g of arginine,
0.4 g of glutamine and an O-3FA:O-6FA
ratio of 5:1 for every 100 mL.
detailed and statistically analysed to
assess comparability. The method of
randomisation was also not detailed and
the study poorly adhered to the CONSORT
standards of reporting.
Postoperative
clinical course
Not reported
Inﬂammatory and
immunological
marker proﬁles
Albumin: p > 0.05
Pre-albumin: on POD9, EIN > SEN
(p < 0.05)
Transferrin: on POD9, EIN > SEN
(p < 0.01)
IgG, IgM, IgA: on POD9, EIN > SEN
(p < 0.05)
CD4/CD8 ratio: on POD9, EIN > SEN
(p < 0.05)
IL-2: on POD9, EIN > SEN (p < 0.05)
IL-6 and TNF-a: on POD9, EIN > SEN
(p < 0.05)
Fujitani et al.,8
2012
Japan
Prospective,
randomised trial
Level II
244 patients undergoing gastrectomy
were randomised to receive either EIN
(n ¼ 127) or SEN (n ¼ 117).
Preoperatively, the EIN group received
1000 mL/day of oral Impact
(Ajinomoto Pharmaceutical Company)
containing 1.28 g of arginine and 0.13 g
of RNA per 100 mL. The O-3FA:O-6FA
ratio was 4:5. The SEN group received
a regular diet with no supplements
Postoperative
complications
(EIN vs. SEN)
Abdominal abscess: 11 (9.2) vs. 7 (6.3)
Pancreatic ﬁstula: 8 (6.7) vs. 7 (6.3)
Anastomotic leakage: 3 (2.5) 3 (2.7)
1$000
Wound infection or dehiscence:
13 (10.8) vs. 8 (7.2)
Drain infection: 3 (2.5) vs. 1 (0.9)
Pneumonia: 5 (4.2) vs. 0 (0)
Venous catheter infection: 2 (1.7) vs.
1 (0.9)
Pleural effusion: 1 (0.8) vs. 1 (0.9)
Postoperative bleeding: 3 (2.5) vs.
0 (0)
Ileus: 2 (1.7) vs. 1 (0.9)
No signiﬁcance difference in any
of the complications above.
This well-designed study concluded that
routine preoperative use of
immunonutrition in well-nourished
patients having gastric cancer resections
could not be recommended.
Postoperative
clinical course
(EIN vs. SEN)
SIRS: 38.3% vs. 30.6% (p > 0.05)
Morbidity rate: 30.8% vs. 26.1% [
RR 1.18 (0.78,1.78)]
Reoperation: 0 vs. 0 (p > 0.05)
Hospital death: 0 vs. 0 (p > 0.05)
Hospital stay (days): 18 (9e85) vs.
17 (10e88) (p > 0.05)
Inﬂammatory and
immunological
marker proﬁles
CRP value on day 3 or 4 (mg/dl):
11 $ 8 (2 $ 3e38 $ 1) vs. 9 $
2 (1 $ 1e38 $ 9) (p > 0.05)
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containing (per 100mL) 0.89 g of arginine,1.3 g of glutamine and an
O-3FA:O-6FA ratio of 3.45:1. The SEN grouped received Nutrison
(Nutricia), a feed containing (per 100 mL) 0.16 g of arginine, 0.4 g of
glutamine and an O-3FA:O-6FA ratio of 5:1. On POD 9, serum levels
of pre-albumin and transferrin were higher in the immunonu-
trition group. On POD 7, the EIN group also had signiﬁcantly higher
levels of IgG, IgM, IgA, CD4 cell counts, CD4:CD8 ratio and IL-2 than
the SEN group. However, IL-6 and TNF-a levels were signiﬁcantly
lower in the immunonutrition group on POD 7. Overall these
ﬁndings suggest that EIN can improve immune mechanisms and
modulate inﬂammatory responses after gastrectomy. The limita-
tions of this study include that the demographics of the groups
were not detailed and statistically analysed to assess comparability.
The method of randomisation was also not detailed and the study
poorly adhered to the CONSORT standards of reporting.
Fujitani et al.,8 randomised 244 patients undergoing gastrec-
tomy to receive either EIN (n ¼ 127) or SEN (n ¼ 117). Preopera-
tively, the EIN group received 1000 mL/day of oral Impact
(Ajinomoto Pharmaceutical Company) containing (per 100 mL)
1.28 g of arginine and 0.13 g of RNA per 100 mL. The O-3FA:O-6FA
ratio was 4:5. The SEN group received a regular diet with no
supplements. No signiﬁcance difference was seen in the rates of
postoperative morbidity or infectious complications. This well-
designed study concluded that routine preoperative use of immu-
nonutrition in well-nourished patients having gastric cancer
resections could not be recommended.
On reviewing all of these studies, there is heterogeneity with
respect to the types of operations undertaken (two studied patients
undergoing oesophagectomy, three studied patients undergoing
gastrectomy and one had patients undergoing both operations). In
addition the RCTs all used different formulations of EIN and SEN,
limiting comparability of the studies. Moreover not all studies re-
ported the same outcomes and in particular, not all studies inves-
tigated similar inﬂammatory and immunological marker proﬁles
limiting the conclusions that can be drawn from these studies.
Finally the quality of the reporting of the RCTs was variable with
some studies not conforming to the CONSORT principles. None-
theless the results of most of the studies demonstrate no deﬁnitive
clinical differences in outcomes with EIN.
8. Clinical bottom line
Although postoperative enteral immunonutrition seems to
improve humoral immunity inpatients undergoing oesophagogastricresection, this improvement does not lead to a reduced hospital stay,
nor does it reduce the rate of infections. There is no convincing
evidence in support of routine immunonutrition in patients under-
going oesophageal or gastric resection for cancer.
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